Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ketoconazole on Lenvatinib PK in Healthy Volunteers
NCT02198170Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2011
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lenvatinib in thyroid cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and 1 more (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Concentration-Time Curve from Zero to Time t and 1 more. Started Feb 2011; status: completed.
02
Drugs
lenvatinib
03
Conditions
thyroid cancerrenal cell carcinoma (RCC)hepatocellular carcinoma (HCC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02198170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02198170.